Content about Ondansetron

March 1, 2013
FDA approves Abilify Maintena for schizophrenia

The Food and Drug Administration has approved a once-monthly treatment for schizophrenia.

TOKYO — The Food and Drug Administration has approved a once-monthly treatment for schizophrenia.

Otsuka Pharmaceutical and H. Lundbeck announced the FDA approval of Abilify Maintena (aripiprazole) for extended-release injectable suspension, an intramuscular depot formulation indicated for the treatment of schizophrenia.

The companies described Abilify Maintena as the first dopamine D2 partial agonist approved as a once-monthly injection, contributing to a new treatment option to address the ongoing need for relapse prevention in patients with schizophrenia.

January 15, 2013
Reports: Otsuka can block Apotex's generic version of Abilify

Drug maker Otsuka Pharmaceuticals can keep generic versions of its schizophrenia drug off the market, according to published reports.

NEW YORK — Drug maker Otsuka Pharmaceuticals can keep generic versions of its schizophrenia drug off the market, according to published reports.

Bloomberg reported that the Supreme Court upheld a ruling that allowed Otsuka to block Canadian generic drug maker Apotex from marketing a version of the antipsychotic Abilify (aripiprazole), which Otsuka co-markets with Bristol-Myers Squibb.

September 11, 2012
Sagent launches drug to prevent chemotherapy-induced vomiting

Sagent Pharmaceuticals has launched a drug used to treat complications related to chemotherapy, the drug maker said.

 SCHAUMBURG, Ill. — Sagent Pharmaceuticals has launched a drug used to treat complications related to chemotherapy, the drug maker said.

The Schaumburg, Ill.-based company announced the launch of ondansetron injection, used to prevent nausea and vomiting associated with emetogenic cancer chemotherapy and also to prevent nausea and vomiting that follows surgery.

Various versions of the drug had sales of $49 million during the 12-month period that ended in June, according to IMS Health.

August 23, 2012
FDA gives Wockhardt tentative approval for bipolar, schizophrenia drug

Indian drug maker Wockhardt has received tentative approval from the Food and Drug Administration for a generic version of a Pfizer psychiatric drug.

PARSIPPANY, N.J. — Indian drug maker Wockhardt has received tentative approval from the Food and Drug Administration for a generic version of a Pfizer psychiatric drug.

Wockhardt announced the tentative approval for ziprasidone hydrochloride in the 20 mg, 40 mg, 60 mg and 80 mg strengths, used to treat bipolar disorder and schizophrenia, and the company plans to launch the drug on Sept. 2, 2012.

July 11, 2011
Amneal launches three generic liquid drugs

Generic drug maker Amneal has launched three new liquid drugs, the company said Monday.

BRIDGEWATER, N.J. — Generic drug maker Amneal has launched three new liquid drugs, the company said Monday.

July 5, 2010
Strativa's Zuplenz receives FDA approval

The Food and Drug Administration has approved a preventive treatment made by Strativa Pharmaceuticals for...

February 7, 2010
FDA issues complete response letter for Zuplenz

The Food and Drug Administration has declined to approve a drug made by Strativa Pharmaceuticals...